导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 0.46% | 2289/4773 |
| 近一周 | -2.43% | 3872/5465 |
| 近一月 | -6.63% | 4250/5421 |
| 近一季 | -13.02% | 4093/5231 |
| 近半年 | -1.78% | 1896/4920 |
| 近一年 | 1.69% | 2437/4394 |
| 近两年 | 56.38% | 1328/2954 |
| 近三年 | 28.20% | 1162/2253 |
| 成立以来 | 78.80% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-1.67% 2421/4961 |
20.62% 1217/5312 |
- - |
- - |
| 2025 | 23.08% 1908/4813 |
-0.47% 2265/3635 |
-0.66% 2990/4076 |
27.88% 1293/4524 |
-2.66% 3183/4813 |
| 2024 | 12.16% 1267/3463 |
0.10% 1042/2808 |
-3.56% 1391/3014 |
19.76% 811/3129 |
-2.99% 2224/3463 |
| 2023 | -15.65% 1655/2656 |
4.24% 1008/2280 |
-6.28% 1614/2385 |
-7.24% 1542/2515 |
-6.93% 1983/2655 |
| 2022 | -24.45% 1218/2207 |
-18.24% 1313/1919 |
8.66% 342/2016 |
-16.39% 1449/2113 |
1.71% 1172/2208 |
| 2021 | -3.67% 923/1822 |
-7.59% 1065/1255 |
11.14% 396/1330 |
-8.33% 1128/1466 |
2.32% 622/1822 |
| 2020 | 48.73% 180/1250 |
-5.35% 412/1028 |
21.33% 235/1067 |
10.75% 516/1164 |
16.93% 144/1184 |
| 2019 | 51.30% 95/1092 |
36.12% 89/754 |
-3.33% 390/804 |
4.20% 213/850 |
10.34% 145/918 |
| 2018 | -32.01% 514/834 |
- - |
- - |
- - |
-12.50% 451/691 |
| 2017 | 23.26% 138/714 |
- - |
- - |
- - |
- - |
| 2016 | -15.49% 359/605 |
- - |
- - |
- - |
- - |
| 2015 | 21.65% 110/575 |
- - |
- - |
- - |
- - |
| 2014 | 31.13% 157/237 |
- - |
- - |
- - |
- - |
| 2013 | -5.01% 93/186 |
- - |
- - |
- - |
- - |
| 2012 | 2.05% 103/140 |
- - |
- - |
- - |
- - |
| 2011 | -30.07% 91/102 |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 港股医疗ETF | 1.4546 | 31.90% |
| 华富中证港股通创新药指数型发起式A | 1.1637 | 30.96% |
| 天弘恒生沪深港创新药精选50ETF发起联接A | 1.3128 | 30.52% |
| 中欧中证港股通创新药指数发起A | 1.6103 | 30.52% |
| 嘉实中证港股通创新药指数发起式C | 0.8566 | 30.50% |
| 中欧中证港股通创新药指数发起C | 1.4583 | 30.44% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8927 | 30.26% |
| 景顺长城中证港股通创新药ETF联接C | 1.4696 | 29.97% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8736 | 29.94% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8719 | 29.88% |
| 银华深证100指数(LOF) VS. 长安沪深300非周期A(740101) |